menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    PharmaTher Updates FDA NDA Status For Ketamine

    GLOBENEWSWIRE

    FDA approves J&J`s ketamine-derived depression treatment

    PRESS RELEASE

    Enforcement Report - Week of January 8, 2025

    FDA

    HOPE, NRx Pharma Experts To Present On PTSD & Depression Treatment

    PR NEWSWIRE

    PharmaTher Updates on FDA NDA for Ketamine

    GLOBENEWSWIRE

    PharmaTher Updates on FDA NDA for Ketamine

    GLOBENEWSWIRE

    NRX-100 (Ketamine) Reaches Stability Milestone

    CONTRACT PHARMA

    Ketabon To Present At-Home Ketamine Therapy At ECNP 2024

    GLOBENEWSWIRE

    PharmaTher Announces Update on FDA NDA for Ketamine

    GLOBENEWSWIRE

    Psychemedics Corporation Launches New Ketamine Hair Testing Service

    GLOBENEWSWIRE

    SciSparc-Clearmind Ketamine-Based Combination Patent Application Published

    GLOBENEWSWIRE

    MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile

    PR NEWSWIRE

    NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter

    PR NEWSWIRE

    NRx Chairman Dr. Javitt to Present at the Ketamine 2024 Conference UK

    PR NEWSWIRE

    Ketamine ER by Douglas Pharmaceuticals for Major Depressive Disorder: Likelihood of Approval

    PHARMACEUTICAL-TECHNOLOGY

    PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX

    GLOBENEWSWIRE

    Enforcement Report - Week of May 24, 2023

    FDA

    Juno Pharmaceuticals Approved to Import Ketamine, Providing Immediate Relief =

    BUSINESSWIRE

    Fresenius` Generic Ketamine Hydrochloride Receives Approval in the U.S.

    FDA

    Melt Pharmaceuticals’ MELT-300 Achieves Primary Sedation Endpoint

    BUSINESSWIRE

    PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine

    GLOBENEWSWIRE

    PharmaTher Announces Poster Presentation +ve Efficacy & Safety Data from Ph1/2

    GLOBENEWSWIRE

    Stigma in drug research holding back new therapies

    ECONOMIC TIMES

    Drugs Effects of Ketamine in Mice can Depend on the Sex of the Human

    NEUROSCIENCENEWS

    Ketamine Ushering in Pharmacology Therapies for Neurological Disorders

    PRNEWSWIRE

    PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine

    GLOBENEWSWIRE

    PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

    GLOBENEWSWIRE

    First patient dosed in second Phase 2 add-on Ketamine Trial in TRD

    GLOBENEWSWIRE

    Enforcement Report - Week of June 8, 2022

    FDA

    PharmaTher grows ketamine portfolio with on-body injector deal

    FIERCEPHARMA

    Prolonged-release ketamine advances after COVID-disrupted trial

    FIERCEPHARMA

    Revitalist and PharmaTher Collaborate for Ketamine Treatment Protocols

    BUSINESSWIRE

    Braxia Provides Update on Large Proprietary Dataset for Ketamine and Psilocybin

    PRNEWSWIRE

    atai Life Sciences announces FDA IND Clearance for PCN-101 R-ketamine Program

    GLOBENEWSWIRE

    PharmaTher Announces FDA Approval of IND Application for Ketamine to Treat ALS

    GLOBENEWSWIRE

    Drug Treatment Delivery Model with Inherently Unfavorable Risk-Benefit Profile

    PRNEWSWIRE

    Osmind to Publish Analysis of Ketamine Infusion Therapy for Depression

    BUSINESSWIRE

    Melt Pharmaceuticals Submits INDs for MELT?210 and MELT-400 to FDA

    BUSINESSWIRE

    University of Exeter: Ketamine Treats Symptoms of Depression, Suicidal Thoughts

    TRIALSITENEWS

    PharmaTher Enters Into Process Development Agreement With LTS LOHMANN

    GLOBENEWSWIRE

    PharmaTher Applies for FDA ODD for Ketamine in Status Epilepticus

    GLOBENEWSWIRE

    Seelos Acquires Exc. License of iX Biopharma`s Wafer-Based Delivery Platform

    PRNEWSWIRE

    Bexson Announces Expansion to Treat Major Depression with Wearable Ketamine

    PRNEWSWIRE

    Braxia Announces Voting Results from Annual General Meeting of Shareholders

    PRNEWSWIRE

    Ketamine`s Potential As A Treatment For Depression Has Drawn Major Industry

    PRNEWSWIRE

    Cybin Announces FDA IND Authorization of Sponsored Feasibility Study

    BUSINESSWIRE

    FDA warns Minnesota doc for running trials without INDs

    ENDPTS

    PharmaTher Engages Alcami for Clinical and Commercial MFG of Novel Ketamine

    GLOBENEWSWIRE

    Ketamine One Launching Two Inaugural Research Studies

    GLOBENEWSWIRE

    Braxia Scientific Reports Encouraging Results of Ketamine Study

    PRNEWSWIRE

    Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine)

    GLOBENEWSWIRE

    AIkido Pharma Files Patent Application for the Use of Ketamine

    PRNEWSWIRE

    PharmaTher Provides Research and Development Update and Milestones for 2021

    GLOBENEWSWIRE

    PharmaTher Expands Patent Portfolio with Filing of U.S. Patent for Ketamine

    GLOBENEWSWIRE

    Seelos Announces Completion of Open-Label Patient Enrollment Study of SLS-002

    PRNEWSWIRE

    Core One Labs Finalizes Deal to Acquire Ketamine Infusions Centers of Texas

    BIOSPACE

    Seelos Announces Dosing of the First Patients in a Study of SLS-002

    PRNEWSWIRE

    Repeated Ketamine Infusions Reduce Symptom Severity in Individuals With Chronic

    NEWSWISE

    After psilocybin and ketamine, a new biotech comes along developing a drug Scott Gottlieb fought

    ENDPTS

    Seelos Therapeutics Announces Final Data from Phase I PK/PD Study

    GLOBENEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.